No abstract

: As compared to other nano polymers, dendrimers have novel three dimensional, synthetic hyperbranched, nano-polymeric structures. The characteristic of these supramolecular dendritic structures has a high degree of significant surface as well as core functionality in the transportation of drugs for targeted therapy, specifically in host-guest response, gene transfer therapy and imaging of biological systems. However, there are conflicting shreds of evidence regarding biological safety and dendrimers toxicity due to their positive charge at the surface. It includes cytotoxicity, hemolytic toxicity, haematological toxicity, immunogenicity and in vivo toxicity. Therefore to resolve these problems surface modification of the dendrimer group is one of the methods. From that point, this review involves different strategies which reduce the toxicity and improve the biocompatibility of different types of dendrimers. From that viewpoint, we broaden the structural and safe characteristics of the dendrimers in the biomedical and pharmaceutical fields.

Introduction: Chronomodulated pulsatile drug delivery system is basically time-controlled drug delivery system in which the release of drug in the body is allowed to match with circadian rhythm with controlled lag time. Aim and Objective: The objective of this work was to develop and evaluate oral pulsatile tablet of Pantoprazole sodium for the treatment of nocturnal hyperacidity. Pulsatile drug delivery system for Pantoprazole sodium was formulated initially as a core tablet followed by press coated. Five different compositions of the core tablet were prepared by using cross carmellose super disintegrant. Base on drug content and dissolution time F5 formulation optimised and proceeds for press coating. Five different compositions of press coating were prepared and evaluated for in vitro drug release. Result: The formulation C4 achieved a maximum of 99.65% cumulative drug release over a period of 3hr. 30 min. Lag time for C4 formulation was found to be 2 hr. It means that the system was found to be satisfactory in terms of drug release after a lag time. Conclusion: Since the developed formulation when taken at bedtime, the tablet would be expected to release the drug at midnight which provides better control with the nocturnal hyperacidity.

No abstract

The present study was performed to determine the therapeutic effects of tioconazole (Tz)-loaded novel transferosome carriers (TFs) for the treatment of atopic dermatitis (AD). Method: Tioconazole transferosomes suspension (TTFs) was formulated and optimized using a 32 factorial design. After that, the optimized batch of TTFs loaded into Carbopol 934 and sodium CMC was prepared with hydrogel and noted as TTFsH. Subsequently, it was evaluated for pH, spread ability, drug content, in vitro drug release, viscosity, in vivo scratching and erythema score, skin irritation, and histopathology study. Result: The optimized batch of TTFs (B4) showed the values of vesicle size, flux, and entrapment efficiency to be 171.40 ± 9.03 nm, 48.23 ± 0.42, and 93.89 ± 2.41, respectively. All batches of TTFsH showed sustained drug release for up to 24 h. The F2 optimized batch released Tz in an amount of 94.23 ± 0.98% with a flux of 47.23 ± 0.823 and followed the Higuchi kinetic model. The in vivo studies provided evidence that the F2 batch of TTFsH was able to treat atopic dermatitis (AD) by reducing the erythema and the scratching score compared to that of the marketed formulation (Candiderm cream, Glenmark). The histopathology study supported the result of the erythema and scratching score study with intact skin structure. It showed that a formulated low dose of TTFsH was safe and biocompatible to both the dermis and the epidermis layer of skin. Conclusion: Thus, a low dose of F2-TTFsH is a promising tool that effectively targeted the skin for the topical delivery of Tz to treat atopic dermatitis symptoms.